Shots:

• The P-III PNEU-PED study evaluates immunogenicity- safety & tolerability of Vaxneuvance (4-dose regimen) vs PCV13 in 1720 infants aged b/w 42-90 days with IPD
• Vaxneuvance showed a non-inferior immune response to PCV13 for 12 & 13 shared serotypes @ 30days- following PD3 & for all 13 based on serotype-specific IgG GMCs- following PD4. The vaccine also showed superior immune responses for shared serotype 3- 22F & 33F & non-inferior immune responses to Ag
• Vaxneuvance also met safety objectives in the P-III PNEU-LINK (V114-031) study in infants. The company plans to submit sBLA to the FDA at the end of 2021

Ref: Merck | Image: Merck